Healthcare Industry News: nasolabial fold
News Release - December 4, 2009
Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer
SAN DIEGO, Calif., Dec. 4 -- (Healthcare Sales & Marketing Network) -- Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this role, Mr. Ranker will lead all Suneva Medical's general and administrative functions including finance, accounting, IT, IR, administration and human resources. He will also serve on the Company's senior management team."One of my key objectives as CFO is to implement financial vigor across all aspects of the business, focusing on maintaining quality controls, utilizing our existing resources responsibly and capitalizing on sound financial management procedures," said Mr. Ranker. "I look forward to contributing to Suneva Medical and joining its seasoned management team in delivering Artefill, a best-in-class product, to our targeted group of physicians in the dermatology, plastic and cosmetic surgery markets."
Prior to joining Suneva Medical, Mr. Ranker served as VP of Finance at Amylin Pharmaceuticals, supporting the company through a significant restructuring which set Amylin on a path toward positive operating cashflow. Prior to Amylin, Mr. Ranker held the positions of CFO and VP of Finance of Nastech Pharmaceutical Company and Director of Finance for ICOS Corporation. He also previously served in various positions in corporate accounting, managed care contracting and research and development, including Senior Finance Director, at Aventis Pharma and its predecessor companies during his nearly fifteen year tenure with the organization. Prior to Aventis, Mr. Ranker was employed by Peat Marwick (currently KPMG) as a CPA.
"We are very pleased to have Phil join the Suneva Management team," said Niv Caviar, President and Chief Executive Officer of Suneva Medical. "Phil brings over twenty-five years of finance and accounting experience within the life science industry and his infrastructure management and strategic planning expertise, coupled with his history of delivering results in his previous roles, will no doubt enhance Suneva's Aesthetic Market growth objectives."
Additional Suneva Medical Corporate Developments:
- Artefill® Market Roll-Out: Since May 2009, Suneva Medical has been actively re-engaging an exclusive group of dermatologists, plastic surgeons and aesthetic physicians about the long-lasting benefits and value of Artefill, the only FDA-approved microsphere-enhanced collagen dermal filler. The response has been overwhelmingly positive as patients continue to seek a filler that will provide long-term wrinkle correction for the nasolabial folds (the lines from the end of the nose to the corners of the mouth). As of December 2009, 20,000+ patients have been successfully treated with Artefill and the numbers continue to grow under the leadership of Suneva Medical and due to the rapid adoption of the technology by skilled physician injectors.
- California State FDA Establishment Inspection: In August 2009, the California State FDA, Food and Drug Branch, determined that Suneva Medical had met the cGMP requirements for a medical device company to legally manufacture and distribute product. Following successful completion of its California State FDA Establishment Inspection and the ISO 13485:2003 Inspections, Suneva Medical began manufacturing and distributing Artefill at its California-based manufacturing facility.
- Long-Term Safety and Patient Satisfaction Clinical Trial: A prospective 5-year study of 1,008 Artefill® patients is currently being conducted to examine the long-term safety and patient satisfaction of Artefill. This trial is currently the largest filler safety trial conducted to-date and the longest-term, longitudinal filler safety trial ever conducted in the U.S. Thus far, the safety results of Artefill have met our expectations and there have been no unexpected safety issues.
- Safety Results to Date. Three years since original approval and with nearly 20,000 patients treated, Artefill®, a 3(rd)-generation, enhanced-formulation PMMA filler, has established an excellent safety profile. Thus far there have been no MDRs, and the safety profile and Adverse Events rates are similar to temporary fillers.
Commenting on these developments, Niv Caviar of Suneva Medical said, "Since our founding in April 2009, we have put into place an experienced senior leadership team that is focused on the long-term success of Artefill and Suneva Medical. We have built great momentum over the past several months and will continue to work diligently to expand our footprint and the market for Artefill in 2010. We will continue to promote Artefill as a unique long lasting product to physicians who wish to offer their patients a safe and long term option to the many temporary fillers in the market."
About Artefill
Artefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. Since Artefill was approved in 2006, over 20,000 patients have been treated successfully with very high satisfaction rates. For more information visit www.artefill.com.
About Suneva Medical
Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company's lead product is Artefill®, the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines. For more information visit www.sunevamedical.com.
Source: Suneva Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
